IMUGENE LIMITED ORDINARY (IMU) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXazer-cel CAR-T naive data presented at ASCO Annual Meeting
other announcement
First Patient in BTKi Combination Cohort of azer-cel study
other announcement
KalkineImugene Advances Cancer Research With Azer-cel Progress
Highlights Azer-cel trial shows encouraging patient responses Study focuses on difficult blood cancer cases Imugene expands immunotherapy research momentum Imugene continues advancing its immuno-oncology pipeline as fresh clinical findings from its azer-cel study highlight encouraging treatment activity in difficult blood cancer cases. Clinical-stage immuno-oncology company Imugene (ASX:IMU) has drawn market attention after releasing fresh clinical findings linked to its azer-cel therap...
Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
other announcement
Change of Director's Interest Notice - PH
director_dealing announcement
Change of Director's Interest Notice - LC
director_dealing announcement
Notice under section 708A(12C)(e) of the Corporations Act
other announcement
Listed Options Top Holders & Holdings Range Report
other announcement
EGM Results and Share Purchase Plan Final Allotment
capital_raise announcement
Change of Director's Interest Notice -LC
director_dealing announcement
Imugene (ASX:IMU) Applies to List Shares After Conversions
Highlights Imugene applies for quotation of additional ordinary shares on ASX New shares arise from conversion of existing securities Capital structure expands slightly within biotechnology operations Imugene has applied to list additional shares following option conversions, reflecting routine capital management activity within its biotechnology operations without materially impacting ownership or operations. The biotechnology sector continues to demonstrate structured capital management act...
Google NewsImugene (ASX:IMU) Applies to List Shares After Conversions - kalkinemedia.com
Imugene (ASX:IMU) Applies to List Shares After Conversions kalkinemedia.com
Azer-cel data to be presented at 2026 ASCO Annual Meeting
other announcement
Notice of Extraordinary General Meeting/Proxy Form
other announcement
Imugene Capital Raise Drives Azer-Cel Cancer Program Forward
Highlights Imugene announces a major capital raising to advance its cancer therapy pipeline. Funds directed toward expansion of the azer-cel clinical program. New clinical cohorts and combination strategies planned in the next phase. Imugene Ltd has unveiled a significant funding initiative aimed at strengthening the development of its azer-cel therapy. The capital raise is designed to expand clinical trials and accelerate progress in innovative immunotherapy research. The announcement ...
$20M placement and SPP, convertible notes amended
capital_raise announcement
100% and 80% ORRs in Subset Indications in azer-cel study
other announcement
Imugene to Present at TD Cowen Annual Health Care Conference
other announcement